Back to Authors

Silverman, Michael

https://orcid.org/0000-0001-8061-6419

A5048598581 | I125749732

Mayo Clinic

Western University

Citations 5

S145 Week 24 Efficacy and Safety Data from PRISM3: A Randomized, Placebo-Controlled Trial Evaluating CP101, an Investigational Orally Administered Microbiome Therapeutic for the Prevention of Recurrent C. difficile Infection

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S63-S64

10.14309/01.ajg.0000773052.38150.f9

S144 CP101 Engraftment Drives Efficacy: Results From a Randomized, Placebo-Controlled Trial Evaluating CP101, an Investigational Orally Administered Microbiome Therapeutic for Prevention of Recurrent C. difficile Infection

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S63-S63

10.14309/01.ajg.0000773048.24890.7e

S131 CP101, an Investigational Orally Administered Microbiome Therapeutic, Increases Intestinal Microbiome Diversity and Prevents Recurrent C. difficile Infection: Results From a Randomized, Placebo-Controlled Trial

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S57-S57

10.14309/01.ajg.0000772996.83378.7c

S0241 American College of Gastroenterology (ACG) Guidelines for Classification of Severity in Colonic Ischemia (CI) Is Useful in Predicting Mortality and Other Adverse Outcomes

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S68-S68

10.14309/01.ajg.0000703012.82954.5e

S0142 Antibiotics Do Not Improve Outcomes in Colon Ischemia (CI) - Results from a Large Retrospective Multi-Center Study

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S68-S68

10.14309/01.ajg.0000702616.45115.0d